Inclusion Criteria:  Health infants and children aged from 3 months to 5 years old. Subject or legal representative who consent and has signed written informed consent. Subject and parent/guardian who is able to comply with all study procedures. Subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination. Subject who haven't immuned with diarrhea vaccination,3-11 months health infants who haven't immuned with Haemophilus b Conjugate vaccination,or had a history of Hib vaccination before the age of 1 but no history of vaccination after 1 year of age,and the interval between the day of the enrollment and the previous dose is more than one month. Axillary temperature ≤37.0 ℃.  Exclusion Criteria:  Febrile illness (temperature ≥ 38°C) in the 3 days or in the acute phase of the disease / active period. Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days. Subject who are allergic to tetanus toxoid. Allergic history after vaccination. Immunodeficiency diseases patients (such as perianal abscess suggests that there may be immunodeficiency in infants and young children) who administered with immunosuppressive agents (≥14 days). Subject who are suffering from serious chronic diseases, cardiovascular disease,liver or kidney disease. Subject with congenital malformations, drug allergies, convulsions, epilepsy, history of craniocerebral trauma, encephalopathy and psychosis, or family history. Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication. Children with abnormal labor（pregnancy week<37w,>42w）,birth weight (<2500g,>4000g), asphyxia rescue history(Only applicable to 3-5 months old group). Subject who plan to participate in or is in any other drug clinical trial. Any condition that, in the judgment of investigator, may affect trial assessment.